ArticleTransplantation direct2026
Intensification of Treosulfan-Fludarabine Conditioning With Thiotepa Exhibited Effectiveness and Tolerability in Older or Comorbid Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With Active Myeloid Neoplasm: A Real-world Study.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reduced-intensity regimens such as treosulfan-fludarabine (TF) are currently considered cornerstones for older or comorbid patients with acute myeloid leukemia and myelodysplastic syndrome (AML/MDS) undergoing allogeneic hematopoietic stem cell transplant (alloSCT). However, data on its use in active disease cases are limited, and intensification strategies (such as thiotepa addition [TTF]) are not standardized in this setting. Methods: To evaluate the efficacy and tolerability of treosulfan-based conditioning in the real-world setting and to provide insights into the use of thiotepa intensification, we retrospectively analyzed 66 (AML, n = 58; MDS, n = 8) patients transplanted between January 2016 and December 2023 at the Hematology Division of Udine, receiving TF (n = 48) or TTF (n = 18). Results: At alloSCT, the median age was 67 y; 37 patients (56%) had a hematopoietic cell transplantation-comorbidity index of >2, and 13 (20%) had received previous alloSCT. Complete remission status was achieved by 52 (79%). A matched donor was used in 35 cases (53%). With a median follow-up of 16 mo, the cumulative incidences of 100-d grade ≥2 acute graft-versus-host disease and 3-y moderate-to-severe chronic graft-versus-host disease were 34% and 21%, respectively. After 3 y, cumulative incidences of nonrelapse mortality and disease relapse were 18% and 40%, with 46% progression-free survival and 52% overall survival. The TTF cohort included more cases with active disease status at alloSCT, both cytological (43% versus 12%, Conclusions: Our results confirmed the efficacy and tolerability of the TF regimen in older or comorbid AML and MDS patients in the real-world setting and suggest that double alkylation might counterbalance the adverse outcome risk posed by active disease at alloSCT. Furthermore, larger, prospective studies are needed to better elucidate the patients for whom the addition of thiotepa might be most beneficial.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.